Medicare is moving fast on GLP-1 pricing. The question is whether employer plans are moving at all.
Two new CMS programs are expanding access to drugs like Wegovy and Zepbound. The Medicare GLP-1 Bridge, launching in 2026, offers access at roughly $245 per month for select medications.
The BALANCE Model, rolling out in 2027, pairs negotiated pricing with required lifestyle support.
Both programs are designed to expand coverage for obesity and related conditions, not just diabetes.
While this is meaningful progress for public programs, it raises a different question for employers.
Medicare Pricing Is Not Employer Pricing
Here is where the disconnect starts.
The economics behind these CMS programs are not automatically available to employer-sponsored plans. Unless a plan has specific structures in place, most employers are still paying significantly higher net costs through traditional PBM contracts.
The gap between what Medicare is working toward and what commercial plans are absorbing is growing. Public programs are pushing costs down.
Employer plans are largely still operating under pricing models that were not built with the employer’s interests at the center.
What Employers Need in Place
To access better economics on GLP-1s, a few things need to be true about how your plan is structured:
-
A carved-out PBM that operates independently from your carrier
-
Transparent pricing so you can see what you are actually paying at the drug level
-
Alternative sourcing strategies that give you access to better net costs
Without these, coverage decisions around GLP-1s are being made without a real cost strategy behind them.
The Bigger Opportunity
Conversations around GLP-1s often focus on whether to cover the medication, but there is more to it than that.
Coverage without a cost strategy is where plans lose control.
The real opportunity is in how these drugs are sourced, managed, and measured over time.
Employers who get that right will be able to offer meaningful benefits without absorbing unsustainable spend.
What This Means for Your Plan
GLP-1 utilization is going up. That is not a question.
The question is whether your plan is structured to handle it, or whether you are going to absorb the full cost of a trend that other programs are already finding ways to manage.
If you are not sure how your current PBM contract handles GLP-1 pricing, that is worth looking into before your next renewal.
JDI Group works with South Florida employers to build benefit strategies that account for exactly this kind of shift. If you want a clearer picture of where your plan stands, we are happy to take a look.
